Clinical trials

  • NIVOLUMAB for Localized melanoma | Resectable stage III cutaneous or mucosal melanoma
  • LY3437943 SODIUM for Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Leriglitazone for Adrenoleukodystrophy
  • N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE for Narcolepsy Type 1 (Narcolepsy with Cataplexy)
  • DS-3790A for Hematological malignancies
  • MITAZALIMAB for Oral potentially malignant disorder | Oral disorders
  • Epinephrine for Chronic spontaneous urticaria
  • TORIPALIMAB for Nasopharyngeal carcinoma (recurrent/metastatic)
  • N-[[(2S)-4-[(4-METHYL-1H-IMIDAZOL-5-YL)METHYL]-3-OXO-2-(PHENYLMETHYL)-1-PIPERAZINYL]CARBONYL]-L-LEUCINE TRIHYDRATE for Cutaneous T-cell lymphoma
  • BISOPROLOL for Pericarditis
  • Nurandociguat for Chronic kidney disease | Arterial hypertension
  • AMPHOTERICIN B for Chronic pulmonary aspergillosis